MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia

Abstract

Acute myeloid leukemia (AML) is an aggressive hematological malignancy, exhibiting high levels of reactive oxygen species (ROS). ROS levels have been suggested to drive leukemogenesis and is thus a potential novel target for treating AML. MTH1 prevents incorporation of oxidized nucleotides into the DNA to maintain genome integrity and is upregulated in many cancers. Here we demonstrate that hematological cancers are highly sensitive to MTH1 inhibitor TH1579 (karonudib). A functional precision medicine ex vivo screen in primary AML bone marrow samples demonstrated a broad response profile of TH1579, independent of the genomic alteration of AML, resembling the response profile of the standard-of-care treatments cytarabine and doxorubicin. Furthermore, TH1579 killed primary human AML blast cells (CD45+) as well as chemotherapy resistance leukemic stem cells (CD45+Lin-CD34+CD38-), which are often responsible for AML progression. TH1579 killed AML cells by causing mitotic arrest, elevating intracellular ROS levels, and enhancing oxidative DNA damage. TH1579 showed a significant therapeutic window, was well tolerated in animals, and could be combined with standard-of-care treatments to further improve efficacy. TH1579 significantly improved survival in two different AML disease models in vivo. In conclusion, the pre-clinical data presented here support that TH1579 is a promising novel anticancer agent for AML, providing a rational to investigate the clinical usefulness of TH1579 in AML in an on-going clinical phase 1 trial. STATEMENT OF SIGNIFICANCEThe MTH1 inhibitor TH1579 is a potential novel AML treatment, targeting both blasts and the pivotal leukemic stem cells while sparing normal bone marrow cells.Research.

OGG1 competitive inhibitors show important off-target effects by directly inhibiting efflux pumps and disturbing mitotic progression

“…Indeed, several highly selective and potent inhibitors of MTH1 have failed to show any cytotoxicity (Kawamura et al, 2016;Kettle et al, 2016;Petrocchi et al, 2016), arguing against a specific effect of MTH1 inhibition being at the origin of cancer cell death. Altogether, it remains unclear if the accumulation of 8-oxoG induced by several MTH1 inhibitors is related to mitotic progression arrest and cancer cell death (Moukengue et al, 2020;Rudd et al, 2020;Sanjiv et al, 2021). However, the effect of SU0268 on mitotic progression observed in this study is probably not related to the accumulation of 8-oxoG as no major effects on the cell cycle progression were observed for TH5487 that also efficiently impairs the repair of 8-oxoG (Supplementary Figures S2,S3).…”

Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer

“…However, only NUDT1 has been in the focus for the development of selective inhibitors, and the other family members have not been chemically targeted so far (44,45). Similar to NUDT18, NUDT1 is a major cleanser of the cytosolic pool of oxidized nucleotides and has been studied as a potential target in several cancer entities (45)(46)(47)(48). Many tumors show increased levels of ROS that can be even beneficial for tumor progression.…”

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia

“…In order to further clarify the therapeutic effect of GNF-7 in vivo, primary bone marrow leukemia cells from of AML#3 and AML#4 were selected to establish PDX models to evaluate the e cacy of GNF-7. Both GNF-7 and gilteritinib signi cantly reduced the in ltration of AML blast cells that expressed with CD45 [21] in the peripheral blood (Fig. 5A, B), with no signi cant difference in effect.…”